Alissa J Cooper1, Steven P Keller2, Christina Chan3, Brett E Glotzbecker4, Michael Klompas5,3, Rebecca M Baron2, Chanu Rhee5,3. 1. Department of Medicine, and. 2. Division of Pulmonary and Critical Care Medicine, and. 3. Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts; and. 4. Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 5. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
Rationale: There have been advances in both cancer and sepsis treatment over the past several decades, yet little is known about trends in sepsis-associated mortality in patients with versus without cancer. Objectives: To assess trends in sepsis-associated mortality in hospitalized patients with and without cancer using objective clinical criteria to identify sepsis and detailed clinical data to adjust for severity of illness. Methods: This was a retrospective cohort study at a tertiary referral hospital and cancer center. Adult in-patients with clinical indicators of sepsis (U.S. Centers for Disease Control and Prevention Adult Sepsis Event criteria) were identified between 2003 and 2014. Patients with cancer were identified using diagnosis codes from their hospitalization or the preceding 90 days. Sepsis-associated in-hospital mortality rates were assessed in 3-year intervals. Multivariable logistic regression models were used to adjust for case mix and severity of illness and to test for subgroup interactions in trends. Results: The cohort included 20,975 patients with sepsis, of whom 7,489 (35.7%) had cancer (61.7% solid and 38.3% hematologic). Sepsis-associated mortality rates in patients with cancer decreased from 31.3% in 2003-2005 to 26.0% in 2012-2014 (absolute decrease, 5.2% [95% confidence interval (CI), 2.3-8.2%]). This mortality reduction persisted after risk adjustment (adjusted odds ratio, 0.53 [95% CI, 0.45-0.63] in 2012-2014 relative to 2003-2005). In contrast, sepsis-associated mortality rates increased in patients without cancer from 20.9% in 2003-2005 to 23.9% in 2012-2014 (absolute increase, 2.1% [95% CI, 0.1-4.1%]), but were stable after risk-adjustment (adjusted odds ratio, 0.90 [95% CI, 0.79-1.03]) (P < 0.001 for comparison of trends between patients with vs. without cancer on both crude and adjusted analysis). Among patients with cancer, declines in risk-adjusted sepsis-associated mortality were observed in both solid and hematologic cancer subgroups, with both community-onset and hospital-onset sepsis, in patients receiving active cancer treatments, and in patients requiring mechanical ventilation at sepsis onset.Conclusions: Sepsis-associated mortality rates declined significantly over a 12-year period in patients with cancer, but not in patients without cancer. Potential explanations include advances in the management of cancer and/or better sepsis treatments specifically in patients with cancer. Further research is needed to elucidate the reasons for our findings and to assess their generalizability to other hospitals.
Rationale: There have been advances in both cancer and sepsis treatment over the past several decades, yet little is known about trends in sepsis-associated mortality in patients with versus without cancer. Objectives: To assess trends in sepsis-associated mortality in hospitalized patients with and without cancer using objective clinical criteria to identify sepsis and detailed clinical data to adjust for severity of illness. Methods: This was a retrospective cohort study at a tertiary referral hospital and cancer center. Adult in-patients with clinical indicators of sepsis (U.S. Centers for Disease Control and Prevention Adult Sepsis Event criteria) were identified between 2003 and 2014. Patients with cancer were identified using diagnosis codes from their hospitalization or the preceding 90 days. Sepsis-associated in-hospital mortality rates were assessed in 3-year intervals. Multivariable logistic regression models were used to adjust for case mix and severity of illness and to test for subgroup interactions in trends. Results: The cohort included 20,975 patients with sepsis, of whom 7,489 (35.7%) had cancer (61.7% solid and 38.3% hematologic). Sepsis-associated mortality rates in patients with cancer decreased from 31.3% in 2003-2005 to 26.0% in 2012-2014 (absolute decrease, 5.2% [95% confidence interval (CI), 2.3-8.2%]). This mortality reduction persisted after risk adjustment (adjusted odds ratio, 0.53 [95% CI, 0.45-0.63] in 2012-2014 relative to 2003-2005). In contrast, sepsis-associated mortality rates increased in patients without cancer from 20.9% in 2003-2005 to 23.9% in 2012-2014 (absolute increase, 2.1% [95% CI, 0.1-4.1%]), but were stable after risk-adjustment (adjusted odds ratio, 0.90 [95% CI, 0.79-1.03]) (P < 0.001 for comparison of trends between patients with vs. without cancer on both crude and adjusted analysis). Among patients with cancer, declines in risk-adjusted sepsis-associated mortality were observed in both solid and hematologic cancer subgroups, with both community-onset and hospital-onset sepsis, in patients receiving active cancer treatments, and in patients requiring mechanical ventilation at sepsis onset.Conclusions: Sepsis-associated mortality rates declined significantly over a 12-year period in patients with cancer, but not in patients without cancer. Potential explanations include advances in the management of cancer and/or better sepsis treatments specifically in patients with cancer. Further research is needed to elucidate the reasons for our findings and to assess their generalizability to other hospitals.
Authors: Chanu Rhee; Sameer Kadri; Susan S Huang; Michael V Murphy; Lingling Li; Richard Platt; Michael Klompas Journal: Infect Control Hosp Epidemiol Date: 2015-11-03 Impact factor: 3.254
Authors: Mark D Williams; Lee Ann Braun; Liesl M Cooper; Joseph Johnston; Richard V Weiss; Rebecca L Qualy; Walter Linde-Zwirble Journal: Crit Care Date: 2004-07-05 Impact factor: 9.097
Authors: Kevin Mo; Arjun Gupta; Humaid Al Farii; Micheal Raad; Farah Musharbash; Britni Tran; Ming Zheng; Sang Hun Lee Journal: J Spine Surg Date: 2022-06
Authors: Robinder G Khemani; Jessica T Lee; David Wu; Edward J Schenck; Margaret M Hayes; Patricia A Kritek; Gökhan M Mutlu; Hayley B Gershengorn; Rémi Coudroy Journal: Am J Respir Crit Care Med Date: 2021-05-01 Impact factor: 21.405
Authors: Ching-Wen Chen; Kelsey B Bennion; David A Swift; Kristen N Morrow; Wenxiao Zhang; Takehiko Oami; Craig M Coopersmith; Mandy L Ford Journal: J Immunol Date: 2021-04-28 Impact factor: 5.422
Authors: Mohammad Alrawashdeh; Michael Klompas; Steven Q Simpson; Sameer S Kadri; Russell Poland; Jeffrey S Guy; Jonathan B Perlin; Chanu Rhee Journal: Chest Date: 2022-01-20 Impact factor: 10.262
Authors: Mohammad Alrawashdeh; Michael Klompas; Simeon Kimmel; Marc R Larochelle; Runa H Gokhale; Raymund B Dantes; Brooke Hoots; Kelly M Hatfield; Sujan C Reddy; Anthony E Fiore; Edward J Septimus; Sameer S Kadri; Russell Poland; Kenneth Sands; Chanu Rhee Journal: Crit Care Med Date: 2021-12-01 Impact factor: 9.296
Authors: Chanu Rhee; Sameer S Kadri; John P Dekker; Robert L Danner; Huai-Chun Chen; David Fram; Fang Zhang; Rui Wang; Michael Klompas Journal: JAMA Netw Open Date: 2020-04-01